{"entity":{"id":"nct06906341","kind":"trial","name":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","aka":[],"tldr":"A phase 2 trial of Relacorilant and Bevacizumab in ovarian cancer and endometrial cancer, run by Corcept Therapeutics, now recruiting.","summary":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers is a phase 2 interventional study registered as NCT06906341 by Corcept Therapeutics, with 270 participants planned, started 2025-04-11 and due to reach its primary completion in 2026-08. Interventions recorded: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2 and Bevacizumab 10 mg/kg.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06906341","url":"https://clinicaltrials.gov/study/NCT06906341"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["relacorilant","bevacizumab"],"companies":["corcept"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06906341","phase":"2","setting":"An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)","sponsor":"Corcept Therapeutics","enrolled":270,"outcomes":[]},"route":"/trials/nct06906341/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/"}],"company":[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/"}]}}